erlotinib hydrochloride has been researched along with Disease, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Massiello, A; Mayton, EK; Mukerjee, P; Murudkar, CS; Park, MA; Pinkerman, RL; Shultz, JC; Wijesinghe, DS | 1 |
| Gemma, A; Saito, Y | 1 |
2 other study(ies) available for erlotinib hydrochloride and Disease, Pulmonary
| Article | Year |
|---|---|
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Topics: Alternative Splicing; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Erlotinib Hydrochloride; HeLa Cells; Humans; Introns; Lung Diseases; Nuclear Proteins; Paclitaxel; Quinazolines; RNA Precursors; RNA Splice Sites; RNA-Binding Proteins; RNA, Antisense; RNA, Small Interfering; Serine-Arginine Splicing Factors | 2011 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |